glp-1 farmacia POV: vienes a la a por un análogo de 👀💉, 👤 “¿Esto es para adelgazar, no?”, 👩‍⚕️ “No exactamente…”, 👤 “¿Entonces lo puede tomar cualquiera?”, 👩‍⚕️ “Tampoco…”, 👤 “¿Y es milagroso?”, 👩‍⚕️ Arkofluido LipoPIC GLP-1 270 g

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

New regulations taking effect on 1 October 2024 will remove compounded semaglutide-containing products from the pharmacy compounding exemption

Treatment options for these conditions are limited to invasive neurosurgery, and novel pharmacological approaches to manage ICP in pathology are sought

Expert guidance on safety, managing side effects, & preventing post-surgery diarrhoea.

This study suggests that GLP-1 agonists effectively reduce BMI, a major risk factor for IIH